EUVIMEDSkopri EUVIMED
KohortenstudieOpen access

App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study

Banshi Saboo, Mudit Sabharwal, Mihir Gharia, Devina Aswal, Parth Modi, Twinkle Maheshwari, Jaymin Parikh, Simpel Saanyal, Jaikishan Agrawal

JMIR Diabetes · 2026-07-08 · 11 · e86651-e86651

DOI: 10.2196/86651 ↗

At a glance

Kohortenstudie in JMIR Diabetes, published online on 2026-07-08. Written by Banshi Saboo and 8 co-authors. Institution: Diabetes Care and Hormone Clinic, Dia Care Research, Ahmedabad, Gujarat, India. 22 references. The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Digital therapeutics integrating continuous glucose monitoring (CGM) with personalized lifestyle coaching can enhance glycemic control in individuals with type 2 diabetes mellitus (T2DM). However, real-world evidence evaluating such multicomponent interventions—combining CGM with nutrition coaching, physiotherapy, and cognitive behavioral therapy within a unified digital platform—remains limited in South Asian populations.

Objective

This study aimed to evaluate the effectiveness of an app-based lifestyle-integrated intervention program (Glycemic Lifestyle Intervention in Diabetes Empowerment–CGM; GLIDE-C) on glycemic, anthropometric, lipid profile, quality of life (QoL), and behavioral outcomes, as well as outcomes related to HEOR (health economics and outcomes research), in adults with mildly uncontrolled T2DM.

Methods

A prospective observational cohort study was conducted among adults aged ≥18 years with confirmed T2DM and baseline hemoglobin A 1c (HbA 1c ) between 7.5% and 9.5%. The intervention was delivered via the Goodflip mobile app, including a 15-day CGM period and a structured analysis of glucose variations, among other clinical assessments, with follow-up on days 15, 30, and 60. The digital intervention combined CGM-guided personalized diet, exercise, and cognitive behavioral therapy plans delivered through the mobile app, supported by multidisciplinary coaching. Primary outcomes were changes in HbA 1c , fasting plasma glucose, postprandial glucose, and CGM metrics; secondary outcomes included lipid profile, anthropometric indices, QoL, and behavioral determinants of glycemic improvement.

Results

Eighteen participants (mean age 49.45, SD 10.91 years; n=11, 61.1% male) completed the program. Mean HbA 1c decreased by 0.59% ( P =.05), with postprandial glucose decreasing by 25.42 mg/dL ( P =.06) and time in range increasing by 9.98%. Modest reductions, consistent with the short intervention duration, occurred in low-density lipoprotein cholesterol (−8.38 mg/dL), body fat (−1.13 kg), and waist circumference (−1.56 cm). QoL improved significantly for sleep quality ( P =.04). Improvements were also observed for motivation ( P =.06), stress management ( P =.08), and mood ( P =.12), although these changes were not statistically significant. Behavioral analysis demonstrated strong associations with glycemic outcomes; all participants who reduced their consumption of energy-dense, nutrient-poor foods experienced improvements in HbA 1c , whereas those who did not reduce energy-dense, nutrient-poor intake showed less favorable outcomes.

Conclusions

The novel GLIDE-C program demonstrated clinically meaningful improvements in glycemic control, behavioral outcomes, and QoL in adults with T2DM, without pharmacological modification. These findings strengthen the role of integrated, CGM-guided digital therapeutic platforms as an effective adjunct to the conventional standard of care.

Subjects

Author keywords

digital therapeuticscognitive behavioral therapycontinuous glucose monitoringlifestyle interventiontype 2 diabetes mellitus

Authors and institutions

  • Diabetes Care and Hormone Clinic, Dia Care Research, Ahmedabad, Gujarat, India.
  • Department of Diabetes and Endocrinology, Dharma Diabetes and Metabolic Clinics, Delhi, India.
  • Department of Medical Affairs, Tatvacare, Purple H 202, Maple County 2, Sindhu Bhavan Road Thaltej, Ahmedabad, Gujarat, 380059, India, +91 9769991897.

Cite

APA

Saboo, B., Sabharwal, M., Gharia, M., Aswal, D., Modi, P., Maheshwari, T., Parikh, J., Saanyal, S., & Agrawal, J. (2026). App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study. JMIR Diabetes, 11, e86651-e86651. https://doi.org/10.2196/86651

Vancouver

Saboo B, Sabharwal M, Gharia M, Aswal D, Modi P, Maheshwari T, et al. App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study. JMIR Diabetes. 2026;11:e86651-e86651. doi:10.2196/86651

BibTeX
@article{Saboo2026,
  author = {Saboo, Banshi and Sabharwal, Mudit and Gharia, Mihir and Aswal, Devina and Modi, Parth and Maheshwari, Twinkle and Parikh, Jaymin and Saanyal, Simpel and Agrawal, Jaikishan},
  title = {App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study},
  journal = {JMIR Diabetes},
  year = {2026},
  volume = {11},
  pages = {e86651--e86651},
  doi = {10.2196/86651}
}
Start for free →